ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Oklahoma » Hematology Oncology

Top Hematology Oncology Prescribers in Oklahoma

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
SCOTT LILLY DDS, MD

Hematology Oncology

12,951

$3.18M

277
116 are 65+

44%
patients receiving schedule two controlled substances

Avg: 15%

45%
patients receiving schedule three controlled substances

Avg: 14%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

35%
prescriptions for brand name drugs

Avg: 19%

$245
Average prescription price

Avg: $394

FRANCISCO DEXEUS M.D.

Hematology Oncology

3,874

$890K

321
252 are 65+

15%
patients receiving schedule two controlled substances

Avg: 15%

16%
patients receiving schedule three controlled substances

Avg: 14%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

17%
prescriptions for brand name drugs

Avg: 19%

$230
Average prescription price

Avg: $394

ALI MOUSSA M.D.

Hematology Oncology

2,617

$1.58M

316
248 are 65+

16%
patients receiving schedule two controlled substances

Avg: 15%

12%
patients receiving schedule three controlled substances

Avg: 14%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

23%
prescriptions for brand name drugs

Avg: 19%

$603
Average prescription price

Avg: $394

SAADIA CHOHAN MD

Hematology Oncology

2,176

$846K

344
286 are 65+

8%
patients receiving schedule two controlled substances

Avg: 15%

15%
patients receiving schedule three controlled substances

Avg: 14%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

12%
prescriptions for brand name drugs

Avg: 19%

$389
Average prescription price

Avg: $394

JESS ARMOR M.D.

Hematology Oncology

2,134

$889K

223
197 are 65+

14%
patients receiving schedule two controlled substances

Avg: 15%

14%
patients receiving schedule three controlled substances

Avg: 14%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

24%
prescriptions for brand name drugs

Avg: 19%

$417
Average prescription price

Avg: $394

BASHAR ALASAD M.D.

Hematology Oncology

2,113

$434K

295
225 are 65+

15%
patients receiving schedule two controlled substances

Avg: 15%

25%
patients receiving schedule three controlled substances

Avg: 14%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

13%
prescriptions for brand name drugs

Avg: 19%

$206
Average prescription price

Avg: $394

RALPH GANICK M.D.

Hematology Oncology

1,939

$573K

209
180 are 65+

0%
patients receiving schedule two controlled substances

Avg: 15%

11%
patients receiving schedule three controlled substances

Avg: 14%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

11%
prescriptions for brand name drugs

Avg: 19%

$296
Average prescription price

Avg: $394

LEONARD BOWEN M.D.

Hematology Oncology

1,883

$982K

216
182 are 65+

11%
patients receiving schedule two controlled substances

Avg: 15%

15%
patients receiving schedule three controlled substances

Avg: 14%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

18%
prescriptions for brand name drugs

Avg: 19%

$522
Average prescription price

Avg: $394

SCOTT MCHAM D.O.

Hematology Oncology

1,874

$890K

311
256 are 65+

13%
patients receiving schedule two controlled substances

Avg: 15%

12%
patients receiving schedule three controlled substances

Avg: 14%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

12%
prescriptions for brand name drugs

Avg: 19%

$475
Average prescription price

Avg: $394

MOHAMED KANAA MD

Hematology Oncology

1,857

$560K

169
143 are 65+

15%
patients receiving schedule two controlled substances

Avg: 15%

15%
patients receiving schedule three controlled substances

Avg: 14%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

20%
prescriptions for brand name drugs

Avg: 19%

$302
Average prescription price

Avg: $394

JOHN LOHREY M.D.

Hematology Oncology

1,782

$578K

225
181 are 65+

16%
patients receiving schedule two controlled substances

Avg: 15%

14%
patients receiving schedule three controlled substances

Avg: 14%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

18%
prescriptions for brand name drugs

Avg: 19%

$324
Average prescription price

Avg: $394

BRIAN GEISTER M.D.

Hematology Oncology

1,688

$538K

212
177 are 65+

16%
patients receiving schedule two controlled substances

Avg: 15%

13%
patients receiving schedule three controlled substances

Avg: 14%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

25%
prescriptions for brand name drugs

Avg: 19%

$319
Average prescription price

Avg: $394

MICHAEL KEEFER M.D.

Hematology Oncology

1,647

$672K

200
175 are 65+

14%
patients receiving schedule two controlled substances

Avg: 15%

14%
patients receiving schedule three controlled substances

Avg: 14%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

18%
prescriptions for brand name drugs

Avg: 19%

$408
Average prescription price

Avg: $394

JAMES HAMPTON M.D.

Hematology Oncology

1,640

$426K

137
120 are 65+

15%
patients receiving schedule two controlled substances

Avg: 15%

10%
patients receiving schedule three controlled substances

Avg: 14%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

20%
prescriptions for brand name drugs

Avg: 19%

$260
Average prescription price

Avg: $394

CRAIG REITZ M.D.

Hematology Oncology

1,600

$490K

188
173 are 65+

11%
patients receiving schedule two controlled substances

Avg: 15%

13%
patients receiving schedule three controlled substances

Avg: 14%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

23%
prescriptions for brand name drugs

Avg: 19%

$306
Average prescription price

Avg: $394

JOSEPH LYNCH MD

Hematology Oncology

1,587

$739K

237
205 are 65+

19%
patients receiving schedule two controlled substances

Avg: 15%

22%
patients receiving schedule three controlled substances

Avg: 14%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

14%
prescriptions for brand name drugs

Avg: 19%

$466
Average prescription price

Avg: $394

ROBERT REYNOLDS MD

Hematology Oncology

1,584

$465K

215
177 are 65+

13%
patients receiving schedule two controlled substances

Avg: 15%

24%
patients receiving schedule three controlled substances

Avg: 14%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

15%
prescriptions for brand name drugs

Avg: 19%

$293
Average prescription price

Avg: $394

JEFFREY DELO MD

Hematology Oncology

1,561

$680K

185
150 are 65+

19%
patients receiving schedule two controlled substances

Avg: 15%

16%
patients receiving schedule three controlled substances

Avg: 14%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

16%
prescriptions for brand name drugs

Avg: 19%

$436
Average prescription price

Avg: $394

VICKI BAKER M.D.

Hematology Oncology

1,457

$382K

239
203 are 65+

18%
patients receiving schedule two controlled substances

Avg: 15%

18%
patients receiving schedule three controlled substances

Avg: 14%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

19%
prescriptions for brand name drugs

Avg: 19%

$262
Average prescription price

Avg: $394

TARIQ MAHMOOD M.D.

Hematology Oncology

1,440

$662K

141
109 are 65+

16%
patients receiving schedule two controlled substances

Avg: 15%

27%
patients receiving schedule three controlled substances

Avg: 14%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

20%
prescriptions for brand name drugs

Avg: 19%

$460
Average prescription price

Avg: $394

KHADER HUSSEIN M.D.

Hematology Oncology

1,427

$673K

157
114 are 65+

20%
patients receiving schedule two controlled substances

Avg: 15%

20%
patients receiving schedule three controlled substances

Avg: 14%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

21%
prescriptions for brand name drugs

Avg: 19%

$471
Average prescription price

Avg: $394

GARY RAHE M.D.

Hematology Oncology

1,295

$692K

121
91 are 65+

21%
patients receiving schedule two controlled substances

Avg: 15%

16%
patients receiving schedule three controlled substances

Avg: 14%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

31%
prescriptions for brand name drugs

Avg: 19%

$534
Average prescription price

Avg: $394

JOHNNY MCMINN M.D.

Hematology Oncology

1,284

$766K

149
108 are 65+

20%
patients receiving schedule two controlled substances

Avg: 15%

24%
patients receiving schedule three controlled substances

Avg: 14%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

19%
prescriptions for brand name drugs

Avg: 19%

$597
Average prescription price

Avg: $394

MANAL ROBIN-HANNA M.D.

Hematology Oncology

1,223

$723K

176
126 are 65+

6%
patients receiving schedule two controlled substances

Avg: 15%

7%
patients receiving schedule three controlled substances

Avg: 14%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

24%
prescriptions for brand name drugs

Avg: 19%

$591
Average prescription price

Avg: $394

ALAN KELLER M.D.

Hematology Oncology

1,199

$610K

147
125 are 65+

12%
patients receiving schedule two controlled substances

Avg: 15%

11%
patients receiving schedule three controlled substances

Avg: 14%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

22%
prescriptions for brand name drugs

Avg: 19%

$509
Average prescription price

Avg: $394

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank